Current Status: GRAD
Graduate Department: Biomedical Engineering
Other Degrees: BS in Biomedical Engineering, Washington University in St. Louis; BSBA in Finance, Washington University in St. Louis;
Advisor(s): Michael E. Davis, PhD;
Hometown: Tegucigalpa, Honduras
I like to read, work out, shop/find super amazing sales, and eat (tons of great restaurants here!). I also like to cook/bake, play basketball, attend dance classes and listen to live music. I enjoy watching and playing sports (in particularly soccer). My wife and I also enjoy doing outdoor stuff (going to parks, hiking) and watching movies. I am also involved in my church, and enjoy hanging out with friends.
Targeted Delivery of VEGF to Ischemic Tissue
In the United States, 8 million people are affected by peripheral artery disease (PAD). Many of these patients do not respond to standard treatments, making amputation their only viable treatment option. New angiogenic therapies are currently being explored as alternative treatments to PAD, such as the delivery of vascular endothelial growth factor (VEGF) to necrotic tissue. Unfortunately, VEGF has numerous side effects and it does not always target the necrotic tissue in PAD. We propose that conjugating VEGF to Hoechst, a compound that targets DNA released by necrotic tissue, will help overcome the limitation of VEGF therapy and improve the clinical outcomes of patients with PAD.